Iguratimod
|
|
|
- CAS-Nr.
- 123663-49-0
- Englisch Name:
- Iguratimod
- Synonyma:
- N-(7-(MethylsulfonaMido)-4-oxo-6-phenoxy-4H-chroMen-3-yl)forMaMide;T 614;CS-1961;IGURATIMOD;Iguratimod >iguratimod( R&D);IguratiMod (T 614);Iguratimod USP/EP/BP;Iguratimod (intermediates I4,I6);N-[7-methanesulfonamido-4-oxo-6-(phenoxy)chromen-3-yl]formamide
- CBNumber:
- CB91011295
- Summenformel:
- C17H14N2O6S
- Molgewicht:
- 374.37
- MOL-Datei:
- 123663-49-0.mol
|
Iguratimod Eigenschaften
- Schmelzpunkt:
- 238.0 to 242.0 °C
- Siedepunkt:
- 580.6±60.0 °C(Predicted)
- Dichte
- 1.52±0.1 g/cm3(Predicted)
- storage temp.
- under inert gas (nitrogen or Argon) at 2-8°C
- Löslichkeit
- DMSO (Slightly)
- Aggregatzustand
- Solid
- pka
- 5.58±0.20(Predicted)
- Farbe
- White to Off-White
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H361 |
Kann vermutlich die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen. |
Reproduktionstoxizität |
Kategorie 2 |
Warnung |
|
P201, P202, P281, P308+P313, P405,P501 |
|
| Sicherheit |
| P201 |
Vor Gebrauch besondere Anweisungen einholen. |
| P202 |
Vor Gebrauch alle Sicherheitshinweise lesen und verstehen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P308+P313 |
BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
| P405 |
Unter Verschluss aufbewahren. |
|
Iguratimod Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
In August 2011, China’s State FDA approved Simcere Pharmaceutical
Group’s new drug application for iguratimod (T-614), a disease modifying
anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis
(RA). Preclinical in vivo studies indicated that iguratimod was effective
in an established adjuvant-induced arthritis model (ED40=3.6 mg/kg)
in rats and also efficacious in a type II collagen-induced arthritis model in DBA/1J mice at 30 mg and 100 mg/kg.
Verwenden
Iguratimod acts as an anti-inflammatory agent, used primarily in the treatment of rheumatoid arthritis.
Clinical Use
Iguratimod, which was discovered by Toyama Pharmaceuticals and jointly co-developed with Eisai in
Japan, was approved by the PMDA (Pharmaceuticals and Medical Devices Agency) of Japan on June 29,
2012 for the treatment of rheumatoid arthritis. This drug was also independently developed by
Simcere Pharmaceutical Group and is marked as Iremod® in China. The drug exhibited inhibitory
effects on granuloma inflammation, and was shown to be efficacious for the prevention of joint
destruction in adjuvant arthritis.
Iguratimod Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Iguratimod Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 277)Lieferanten
123663-49-0()Verwandte Suche:
- iguratimod( R&D)
- T 614
- N-[7-methanesulfonamido-4-oxo-6-(phenoxy)chromen-3-yl]formamide
- 3-(Formylamino)-7-(methylsulfonylamino)-6-phenoxy-4H-1-benzopyran-4-one
- N-[3-(Formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]methanesulfonamide
- IguratiMod (T 614)
- IGURATIMOD
- CS-1961
- N-[7-(methanesulfonamido)-4-oxo-6-phenoxy-1-benzopyran-3-yl]formamide
- Iguratimod >
- Methanesulfonamide, N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-
- N-(3-Formamido-4-oxo-6-phenoxy-4H-chromen-7-yl)methanesulfonamide
- N-[7-(Methanesulfonamido)-4-oxo-6-phenoxy-4H-chromen-3-yl]formamide
- Iguratimod USP/EP/BP
- IguratimodQ: What is
Iguratimod Q: What is the CAS Number of
Iguratimod Q: What is the storage condition of
Iguratimod Q: What are the applications of
Iguratimod
- N-(7-(MethylsulfonaMido)-4-oxo-6-phenoxy-4H-chroMen-3-yl)forMaMide
- Iguratimod (intermediates I4,I6)
- N-(7-(Methylsulfonamido)-4-oxo-6-phenoxy-4H-chromen-3-yl)formamide (Iguratimod Impurity)
- 123663-49-0
- Pharmaceutical intermediate
- Pharmaceuticals
- API
- 123663-49-0
